Background and objectives Infectious complications remain a significant cause of peritoneal dialysis (PD) technique failure. Topical ointments seem to reduce peritonitis; however, concerns over resistance have led to a quest for alternative agents. This study examined the effectiveness of applying topical Polysporin Triple ointment (P 3 ) against mupirocin in a multi-centered, double-blind, randomized controlled trial.
Introduction
Peritonitis is the most significant complication associated with peritoneal dialysis (PD). It is a cause of considerable morbidity and may lead to technique failure and lengthy hospitalization. Furthermore, recent data suggest that peritonitis may be a contributing factor in 15% of PD deaths and that each episode of peritonitis carries a 4%-8% risk of mortality (1, 2) .
Historically, PD catheter-related infections have been predominantly caused by organisms found on skin surfaces, such as Staphylococcus epidermis and Staphylococcus aureus. However, in recent years, there is an increasing proportion of exit-site infection and catheter-related peritonitis caused by Pseudomonas aeruginosa and other Gram-negative organisms. On the basis of current evidence, current clinical practice guidelines (3) suggest the routine use of a topical agent at the PD catheter exit site and two agents, mupirocin and gentamicin, are recommended. Mupirocin has been, and currently remains, widely used globally. It is a topical antibiotic cream or ointment that has excellent activity against Gram-positive organisms but has little or no effect against Pseudomonas or other Gram-negative bacteria. Several studies comparing mupirocin with placebo have shown a reduction in exit-site infection and peritonitis with the topical application of nasal or exit-site mupirocin, largely driven by a decrease in S. aureus infection (4) (5) (6) (7) (8) (9) (10) (11) (12) . Gentamicin is an aminoglycoside antibiotic that may either be used topically as a prophylactic agent or systemically as a treatment for documented infection. It has excellent antibacterial activity against Gram-negative organisms like P. aeruginosa and also against some Gram-positive organisms, including S. aureus. In a randomized controlled trial comparing gentamicin to mupirocin in prevalent PD patients, a reduction in Gram-negative peritonitis was seen without an increase in Gram-positive infections (13) . Two subsequent, nonrandomized studies failed to confirm the superiority of gentamicin over mupirocin (14, 15) . Despite the robust, randomized, controlled nature of the data, the inclusion of multiple interim analyses for safety reasons increased the risk of a false positive result to 34% (16) . This observation, coupled with concerns that widespread use of topical gentamicin may lead to bacterial resistance, has led to a continued search for new agents.
Polysporin Triple (P 3 ; bacitracin 500 U/g, gramicidin 0.25 mg/g, and polymyxin B 10,000 U/g) is an alternative topical ointment that has been used with success for some years in the hemodialysis (HD) population (17) . Compared with placebo ointment, P 3 applied to the exit site of HD patients dialyzed with a tunnelled temporary or semipermanent dialysis catheter reduced infections (18) . In addition to being inexpensive and easily available, P 3 is attractive because it has bacteriostatic activity against a wide range of both skin flora and other organisms, including Gram-negative bacteria (19) .
The aim of this study was to ascertain whether the application of P 3 ointment was superior to mupirocin when routinely applied at the PD catheter exit site in the prevention of PD-related infections.
Materials and Methods
A detailed account of the methods used in this study was previously published (20) . This was a multi-center, doubleblind, randomized controlled trial of two active treatments. Ointments were prepared and dispensed by a central clinical trials pharmacy, and were similar in color, odor, and consistency. PD patients from each of the three participating sites were eligible for inclusion if they were aged $18 years and were medically stable as defined by their nephrologist. Both prevalent and incident patients were included. Informed consent was obtained. Exclusion criteria included patients with ARF; catheter-related infection at the time of recruitment or in the previous 3 months; use of an oral, intravenous, or intraperitoneal antibiotic at the time of randomization or in the past 1 week; a known allergy to any component of P 3 or mupirocin; or a scheduled date for living donor transplant surgery within 6 months of the study completion date. Centrally allocated permuted block randomization was used to assign patients to either mupirocin or P 3 ointment. Stratification groups were based on the center, whether an incident or prevalent patient, and the use of a cycler. Patients were instructed to apply the ointment to the exit site using a cotton-tipped applicator with each dressing change, and were specifically advised not to use any other exit-site applications outside the protocol. All other aspects of medical care, including the management of PD-related infections, were left to the discretion of the patient's primary nephrologist.
Patients were followed in person and by telephone at monthly intervals. To determine whether patients had additional hospitalizations and intercurrent illnesses, we screened daily hospital admission logs and reviewed the minutes from the weekly clinical meetings in which patients with ongoing PD-related issues were reviewed. The primary end point was the time to first PD-related infection. This was a composite end point that included one or more of the following: exit-site infection, tunnel infection, or PD peritonitis, as defined by International Society of Peritoneal Dialysis guidelines. Secondary end points included the removal of the catheter for refractory infection, hospitalization due to PD-related infection, death due to PD-related infection, all-cause mortality, and transfer to HD. This study was approved by the hospital research ethics board at each of the participating sites. The data safety monitoring board recommended continued follow-up even after the first PD-related infection for subsequent safety data analysis. As such, followup was continued in all patients until death, transfer to another unit, transplantation, or the end of the 18-month follow-up period. Patients electively switching to HD were advised to continue routine exit-site care, and were followed for infections until PD catheter removal.
Statistical Analyses
The sample size was estimated at 100 participants in each arm, on the basis of an accrual period of 6 months and a follow-up period of 18 months, and an instantaneous hazard ratio of 0.045 for the standard treatment group versus 0.023 for the P 3 group to achieve a power of 81%, with an a of 0.05 (20) .
Descriptive data were reported as mean 6 SD or as median 6 quartiles. The composite end point was compared using a Kaplan-Meier curve and log rank comparisons. Peritonitis and exit-site rates were calculated for each individual based on their follow-up time. Rates were calculated as the number of events occurring divided by the total follow-up days. Post hoc comparisons between groups for hospitalization, mortality, and infection rates were done using Kaplan-Meier curves and log rank comparisons, and Poisson regression as appropriate. All statistical analyses were performed using PASW software (version 17.2; SPSS Inc, Chicago, IL).
Results
A total of 387 patients were assessed for eligibility ( Figure 1) . We recruited 204 patients from 3 sites. However, because of unforeseen difficulties, recruitment from one of the sites was discontinued and the data were excluded (n=3). The remaining 201 patients from two centers were randomly assigned to either mupirocin (n=100) or P 3 (n=101) using stratified block randomization as per protocol. The baseline characteristics of these 201 patients are shown in Table 1 . There were no differences in terms of age, sex, comorbidities, methicillin-resistant S. aureus carriage, PD modality, or time on dialysis between the two groups.
Patients were followed for a total of 2742 patient-months (median 18 months; range, 0.1-18 months). Eighty-seven patients (45%) were followed for ,18 months due to death, premature study withdrawal, or PD catheter removal (Figure 1) . No statistical difference was found for the time to first PD-related infection (P=0.41) (Figure 2 ). In total, 75 patients had a PD-related infection, including 36 patients from the mupirocin group and 39 from the P 3 group (Table 2) . Fiftyone study events were due to episodes of peritonitis, of which 23 occurred in the P 3 group and 28 occurred in the mupirocin group. There were twice as many exit-site infections in the group assigned to receive P 3 , although this did not reach statistical significance (P=0.09). No tunnel infections occurred during the study period. To note, patients in the P 3 group were at increased risk of reaching the primary endpoint because of fungal infection compared with those randomized to mupirocin (7 versus 0; P=0.01). This finding was largely driven by fungal exit-site infection. There was no difference in the number of infections seen by center, PD modality, or incident versus prevalent patient groups. Secondary outcomes are shown in Table 3 . Hospitalization rates were similar in both groups.
Data collected over the duration of the study (total followup time of 120.2 and 108.2 patient-years for mupirocin and P 3 , respectively) showed an overall PD-related infection rate of 0.59 per patient-year (1 in 17 patient-months). The overall peritonitis rate in study participants was 0.39 per patient-year (1 in 26 patient-months) with no statistical difference between those randomized to mupirocin or P 3 (0.40 versus 0.37, respectively). The observed exit-site infection rate was 0.19 per patient-year with significantly higher rates in those randomized to the P 3 group than in the mupirocin group (0.28 versus 0.12, respectively; P=0.02). There was a highly significant increase in the rate of fungal infections, both exit-site infections (0.07 versus 0.01 episodes per patient-year) and episodes of peritonitis (0.04 versus 0.00 episodes per patient-year), seen in association with P 3 (Table 4) . None of the patients with fungal infection had exposure to oral or systemic antibiotics in the previous 3 months. Rash was a common side effect reported by patients, particularly in those randomized to P 3 (14 versus 6 for P 3 and mupirocin, respectively). There were two protocol violations (one in each of the two study groups). In both cases, the patients presented to an emergency department, and had a dressing change performed using mupirocin on one occasion before resuming their normal study drug.
Discussion
In this study, application of P 3 to the PD catheter exit site was not shown to be superior to exit-site mupirocin in the prevention of PD-related infections. Patients randomized to mupirocin seemed to have fewer exit-site infections and a higher risk of Gram-negative peritonitis. However, the total number of catheter-related infections and the time to these infections were similar in both groups. Furthermore, over the full follow-up period, there was a higher frequency of fungal exit-site infection and fungal peritonitis among patients receiving P 3 .
The major reasons for the lack of superiority of P 3 over mupirocin likely relate to the frequency and type of infections that occurred in this study. Specifically, although the P 3 group had fewer Gram-negative peritonitis episodes than the mupirocin group, the total number of episodes of Gram-negative peritonitis and exit-site infection were low, limiting the potential benefit of P 3 over mupirocin. In addition, any small signal toward benefit in the P 3 group resulting from better Gram-negative coverage was negated by the increased frequency of fungal infection.
The finding of an increased risk of fungal infections with P 3 is consistent with one report in the HD literature of an increased incidence of exit-site infection with P 3 (21) . In larger series in which P 3 was used for several years for exit-site prophylaxis at the central venous catheter site, no increase in fungal infection was seen (17) . However, it is known that broad-spectrum antibacterial agents can alter local flora and lead to overgrowth of fungal organisms.
One example of this is the increased risk of fungal peritonitis among PD patients who have received antibiotics in the prior few months (22) (23) (24) (25) . Interestingly, in the randomized trial by Bernardini et al. (13) comparing topical mupirocin with gentamicin, there was a signal toward a greater number of fungal exit-site infections among patients who received gentamicin (without an increase in fungal peritonitis) together with a lower Gram-negative peritonitis rate similar to that demonstrated in our study. The likelihood of fungal colonization and potential infection may relate to the extent to which the patient's endogenous skin flora is altered. The three agents in P 3 collectively offer comparatively more broad-spectrum coverage than gentamicin alone; however, gentamicin has wider coverage than mupirocin. If interpreted together with the observations that P 3 has more fungal colonization than gentamicin and that gentamicin has more colonization than mupirocin, we propose that there is a trade-off between the benefits of broad-spectrum activity against many potential pathogens and the risk of fungal colonization and infection.
With this in mind, the clinical significance of fungal exitsite infection in PD patients remains unclear. On the basis of our data, no patients with fungal exit-site infection went on to develop fungal peritonitis over the duration of followup. However, there were also four fungal peritonitis episodes in the P 3 group over the 18-month follow-up period, and these could not be attributed to systemic use of antibiotics in the prior few months. Although the number of fungal peritonitis episodes in the P 3 is small, the potential for morbidity and mortality as a result of a fungal peritonitis episode is high.
This study, as with all studies, has both strengths and limitations. The strengths include conformation to the original study protocol, sufficient events to meet predicted study power, and maintenance of blinding. The observed event and drop-out rates were similar to those predicted in the sample size calculation, suggesting that the study is adequately powered to have shown a benefit with P 3 had one been present. Thus, the negative findings of this study strongly suggest a lack of superiority of P 3 over mupirocin. In both centers, the compliance with randomization and outcome event reporting was high and the overall peritonitis rate was consistent with city-wide trends both before and after this study. The two protocol violations were short and consequently unlikely to have affected the study outcome. This study is limited by the high number of patients randomized to P 3 who requested to be withdrawn from the study because of a rash or irritation associated with the use of the ointment; however, the attrition rate is not higher than that predicted initially. Rash is a recognized side effect of P 3 . However, in our HD experience, rash is found to resolve if application with the ointment is continued. We were struck by the high incidence of both exit-site infection and irritation with P 3 , and hypothesized that this combination may have been attributed to a misdiagnosis bias. We hypothesized that skin irritation might have prompted more frequent swabbing of the exit site in the P 3 group, and, if colonization was present, subsequently led to a misdiagnosis of infection. Presuming that skin irritation with P 3 would be more likely to occur within the first few weeks to months, we hypothesized that exit-site infections would be more commonly reported in the P 3 group within the first few months of the study. Using Kaplan-Meier survival analysis, we compared the time to first exit-site infection and found no early risk in the P 3 group (data not shown), arguing against misdiagnosis.
In conclusion, we do not recommend the use of P 3 ointment for prophylaxis against PD catheter-related infections. Despite its broad-spectrum coverage, P 3 does not seem to offer benefits as a prophylactic agent over those provided by mupirocin. Furthermore, concerns about fungal colonization and fungal peritonitis suggest that P 3 should be used with caution in the PD population.
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